Secukinumab

Drug Profile

Secukinumab

Alternative Names: AIN-457; Cosentyx; Human anti-interleukin-17A monoclonal antibody; KB-03303A; NVP-AIN 457

Latest Information Update: 22 Dec 2016

Price : $50

At a glance

  • Originator Alcon; Novartis
  • Developer Icahn School of Medicine at Mount Sinai; Novartis
  • Class Anti-inflammatories; Monoclonal antibodies
  • Mechanism of Action Interleukin-17 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Plaque psoriasis; Psoriatic arthritis
  • Registered Ankylosing spondylitis; Pustular psoriasis
  • Phase III Psoriasis; Rheumatoid arthritis
  • Phase II Alopecia areata; Atopic dermatitis
  • Discontinued Asthma; Crohn's disease; Dry eyes; Multiple sclerosis; Polymyalgia rheumatica; Type 1 diabetes mellitus; Uveitis

Most Recent Events

  • 08 Nov 2016 Novartis initiates a phase IV STEPin trial for Plaque psoriasis in Finland (EudraCT2015-002423-26)
  • 12 Oct 2016 Novartis completes a phase III trial in Plaque psoriasis in Germany (EudraCT2014-001974-32) prior to October 2016
  • 12 Oct 2016 Novartis completes the phase III PRIME trial in Plaque psoriasis in Germany (EudraCT2014-005258-20) prior to October 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top